ORCHPHARMA vs SHILPAMED: Stock Comparison

Orchid Pharma Limited vs Shilpa Medicare Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Shilpa Medicare Limited is the larger company by market capitalisation. Shilpa Medicare Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Orchid Pharma Limited and Shilpa Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ORCHPHARMA is more favourable on 1 of 13 scored metrics and SHILPAMED on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SHILPAMED is the larger company
₹11,839 Cr vs ₹5,001 Cr
P/E Ratio
SHILPAMED has a lower P/E
48.66x vs 243.46x
P/B Ratio
ORCHPHARMA has a lower P/B
3.88x vs 4.57x
EPS
SHILPAMED has higher earnings per share
₹12.44 vs ₹4.01
Dividend Yield
SHILPAMED has a higher dividend yield
0.08% vs 0%
Revenue Growth (TTM YoY)
SHILPAMED has faster revenue growth
31.5% vs -1.5%
EPS Growth (TTM YoY)
SHILPAMED has faster EPS growth
644.6% vs 0%
Qtr Sales Growth
SHILPAMED has stronger quarterly sales growth
32.1% vs 0.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricORCHPHARMASHILPAMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricORCHPHARMASHILPAMED
Live Price₹985.35₹605.2
Day Change-0.26%-2.48%
Volume43,8754.34 L
52-Week High₹1,119.8₹860
52-Week Low₹480₹259.5
Distance from 52W High-12.01%-29.63%

Valuation

MetricORCHPHARMASHILPAMED
Market Cap₹5,001 Cr₹11,839 Cr
P/E Ratio243.46x48.66x
P/B Ratio3.88x4.57x
EPS₹4.01₹12.44
Book Value₹253.98₹132.46
Dividend Yield0%0.08%

Growth

MetricORCHPHARMASHILPAMED
Revenue Growth (TTM YoY)-1.5%31.5%
EPS Growth (TTM YoY)0%644.6%
Qtr Sales Growth0.05%32.1%
Qtr Profit Growth4.26%148%

Profitability & Leverage

MetricORCHPHARMASHILPAMED
ROE2.12%9.4%
ROCE2.64%11%
Net Margin2.51%15.82%
Operating Margin5.07%28.2%
Debt to Equity0.28x0.25x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricORCHPHARMASHILPAMED
Promoter Holding69.84%40.13%
FII Holding0.81% 0.06 pp11.38% 0.3 pp
DII Holding20.75% 0.5 pp8.05% 0.53 pp
Public Holding8.61% 0.44 pp40.43% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Orchid Pharma Limited and Shilpa Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.